New 52 Week High Today

My Portfolio
+
LINK YOUR PORTFOLIO

Neurocrine Biosciences, Inc NBIX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:13 PM EDT
166.03quote price arrow up+0.92 (+0.56%)
Volume
171,704
Close
165.11quote price arrow up+10.27 (+6.63%)
Volume
1,769,674
52 week range
122.14 - 165.81
Loading...
  • Open155.56
  • Day High165.81
  • Day Low155.12
  • Prev Close154.84
  • 52 Week High165.81
  • 52 Week High Date06/03/26
  • 52 Week Low122.14
  • 52 Week Low Date02/12/26

Key Stats

  • Market Cap16.602B
  • Shares Out100.55M
  • 10 Day Average Volume1.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.40

KEY STATS

  • Open155.56
  • Day High165.81
  • Day Low155.12
  • Prev Close154.84
  • 52 Week High165.81
  • 52 Week High Date06/03/26
  • 52 Week Low122.14
  • 52 Week Low Date02/12/26
  • Market Cap16.602B
  • Shares Out100.55M
  • 10 Day Average Volume1.13M
  • Dividend-
  • Dividend Yield-
  • Beta0.40

RATIOS/PROFITABILITY

  • EPS (TTM)6.50
  • P/E (TTM)25.40
  • Fwd P/E (NTM)20.88
  • EBITDA (TTM)828.60M
  • ROE (TTM)22.50%
  • Revenue (TTM)3.102B
  • Gross Margin (TTM)98.17%
  • Net Margin (TTM)21.55%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/28/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as...
William Rastetter Ph.D.
Independent Chairman of the Board
Kyle Gano Ph.D.
President, Chief Executive Officer, Director
Matthew Abernethy CPA
Chief Financial Officer
Address
6027 EDGEWOOD BEND COURT
San Diego, CA
92130
United States